Year-end report

Increased sales and continued strategic investments

The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit the year-end report for the fiscal year 2017/18.

For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
E-mail: ir@phiab.se
Web: www.phiab.se

Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.